MT-101 IMAGINE Phase 1/2 Study
MT-101 is being developed for the treatment of relapsed and refractory CD5-expressing T-cell lymphomas. Refractory PTCL is a lethal disease with limited treatment options that, until now, has not benefited from innovations in cell therapy. In vitro and in vivo studies show MT-101 demonstrated meaningful anti-tumor activity.
MT-302 SYMPHONY Phase 1 Study
MT-302 represents the first candidate in an entirely new, therapeutic modality. It is a first-in-class, TROP2-FcA-LNP, with a strong preclinical profile that supports its advance into this first-in-human trial. TROP2 is overexpressed in most human solid epithelial cancers, with lower expression in corresponding normal tissue. Increased TROP2 expression has been linked to tumor growth.
Join our Studies
Myeloid has dosed its first patient in the IMAGINE study — a Phase 1/2, multicenter, open-label, dose-escalation, and dose cohort expansion clinical trial evaluating MT-101 in patients with refractory or relapsed PTCL. The dose-escalation portion of this Phase 1 study is currently open and enrolling patients with and without conditioning therapy.
Myeloid has also started dosing patients in the Symphony Study for MT-302 – a Phase 1 study (NCT05969041), which is an open-label dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of MT-302 in adults with advanced or metastatic epithelial tumors that overexpress TROP2. This study will also define the recommended Phase 2 dose (RP2D) of MT-302. The study is currently enrolling patients at multiple clinical sites in Australia.
Once Myeloid establishes the recommended Phase 2 dose, a Phase 2 trial will be initiated to support registration in this patient population.
Access to MT-101 Outside of a Clinical Trial Is Not Currently Available
We recognize the unmet treatment need in patients with T-cell lymphoma who do not qualify for a clinical trial. Myeloid will put into place an expanded access policy once more therapeutic experience is available.